Teva Pharmaceutical Industries (TEVA) Convertible Debt (2009 - 2010)
Teva Pharmaceutical Industries' (TEVA) quarterly Convertible Debt came in at $13.0 million in Q4 2010, down 98.41% YoY from $817.0 million in Q4 2009, and down 7.14% on a QoQ basis from $14.0 million in Q3 2010.
Teva Pharmaceutical Industries (TEVA) Convertible Debt (2009 - 2010) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 2 years of Convertible Debt data on file, last reported at $13.0 million in Q4 2010.
- Quarterly Convertible Debt fell 98.41% year-over-year to $13.0 million in Q4 2010, while the trailing twelve-month figure through Dec 2010 was $13.0 million (down 98.41% YoY) and the FY2010 annual result came in at $13.0 million, down 98.41% from the prior year.
- Convertible Debt declined to $13.0 million in Q4 2010, from $14.0 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $1.2 billion in Q1 2009 to a low of $13.0 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 13.00 Mn |
| Sep 30, 2010 | 14.00 Mn |
| Jun 30, 2010 | 21.00 Mn |
| Mar 31, 2010 | 47.00 Mn |
| Dec 31, 2009 | 817.00 Mn |
| Sep 30, 2009 | 832.00 Mn |
| Jun 30, 2009 | 861.00 Mn |
| Mar 31, 2009 | 1.21 Bn |